Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3

citation_journal_title=J Immunother Cancer; citation_title=Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer; citation_author=RR Raval, AB Sharabi, AJ Walker, CG Drake, P Sharma; citation_volume=2; citation_publication_date=2014; citation_pages=14; citation_doi=10.1186/2051-1426-2-14; citation_id=CR1 citation_journal_title=Semin Oncol; citation_title=Anticancer therapy targeting the erbB family of receptor tyrosine kinases; citation_author=WJ Slichenmyer, DW Fry; citation_volume=28; citation_publication_date=2001; citation_pages=67-79; citation_doi=10.1016/S0093-7754(01)90284-2; citation_id=CR2 citation_journal_title=Breast Cancer Res; citation_title=Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing; citation_author=M Schmidt, B Lewark, N Kohlschmidt, C Glawatz, E Steiner, B Tanner, H Pilch, W Weikel, H Kolbl, HA Lehr; citation_volume=7; citation_publication_date=2005; citation_pages=R256-R266; citation_doi=10.1186/bcr991; citation_id=CR3 citation_journal_title=Oncologist; citation_title=The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy; citation_author=JS Ross, JA Fletcher; citation_volume=3; citation_publication_date=1998; citation_pages=237-252; citation_id=CR4 citation_journal_title=Cancer Immunol Immunother; citation_title=Anti-HER2 vaccines: new prospects for breast cancer therapy; citation_author=MZ Ladjemi, W Jacot, T Chardes, A Pelegrin, I Navarro-Teulon; citation_volume=59; citation_publication_date=2010; citation_pages=1295-1312; citation_doi=10.1007/s00262-010-0869-2; citation_id=CR5 citation_journal_title=Biochim Biophys Acta; citation_title=The biology of erbB-2/neu/HER-2 and its role in cancer; citation_author=NE Hynes, DF Stern; citation_volume=1198; citation_publication_date=1994; citation_pages=165-184; citation_id=CR6 citation_journal_title=Nat Med; citation_title=Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets; citation_author=RA Clynes, TL Towers, LG Presta, JV Ravetch; citation_volume=6; citation_publication_date=2000; citation_pages=443-446; citation_doi=10.1038/74704; citation_id=CR7 citation_journal_title=Clin Cancer Res; citation_title=Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2; citation_author=R Gennari, S Menard, F Fagnoni, L Ponchio, M Scelsi, E Tagliabue, F Castiglioni, L Villani, C Magalotti, N Gibelli, B Oliviero, B Ballardini, G Da Prada, A Zambelli, A Costa; citation_volume=10; citation_publication_date=2004; citation_pages=5650-5655; citation_doi=10.1158/1078-0432.CCR-04-0225; citation_id=CR8 citation_journal_title=Br J Cancer; citation_title=Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?; citation_author=L Arnould, M Gelly, F Penault-Llorca, L Benoit, F Bonnetain, C Migeon, V Cabaret, V Fermeaux, P Bertheau, J Garnier, JF Jeannin, B Coudert; citation_volume=94; citation_publication_date=2006; citation_pages=259-267; citation_doi=10.1038/sj.bjc.6602930; citation_id=CR9 citation_journal_title=N Engl J Med; citation_title=Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer; citation_author=MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, I Smith, L Gianni, J Baselga, R Bell, C Jackisch, D Cameron, M Dowsett, CH Barrios, G Steger, CS Huang, M Andersson, M Inbar, M Lichinitser, I Lang, U Nitz, H Iwata, C Thomssen, C Lohrisch, TM Suter, J Ruschoff, T Suto, V Greatorex, C Ward, C Straehle, E McFadden, MS Dolci, RD Gelber; citation_volume=353; citation_publication_date=2005; citation_pages=1659-1672; citation_doi=10.1056/NEJMoa052306; citation_id=CR10 citation_journal_title=Mol Cancer Ther; citation_title=Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling; citation_author=P Mullen, DA Cameron, M Hasmann, JF Smyth, SP Langdon; citation_volume=6; citation_publication_date=2007; citation_pages=93-100; citation_doi=10.1158/1535-7163.MCT-06-0401; citation_id=CR11 citation_journal_title=Cancer Cell; citation_title=Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth; citation_author=DB Agus, RW Akita, WD Fox, GD Lewis, B Higgins, PI Pisacane, JA Lofgren, C Tindell, DP Evans, K Maiese, HI Scher, MX Sliwkowski; citation_volume=2; citation_publication_date=2002; citation_pages=127-137; citation_doi=10.1016/S1535-6108(02)00097-1; citation_id=CR12 citation_journal_title=Cancer Res; citation_title=Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects; citation_author=JG Jackson, P St Clair, MX Sliwkowski, MG Brattain; citation_volume=64; citation_publication_date=2004; citation_pages=2601-2609; citation_doi=10.1158/0008-5472.CAN-03-3106; citation_id=CR13 citation_journal_title=Cancer Res; citation_title=The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells; citation_author=R Nahta, MC Hung, FJ Esteva; citation_volume=64; citation_publication_date=2004; citation_pages=2343-2346; citation_doi=10.1158/0008-5472.CAN-03-3856; citation_id=CR14 citation_journal_title=Cancer; citation_title=2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth; citation_author=N Takai, A Jain, N Kawamata, LM Popoviciu, JW Said, S Whittaker, I Miyakawa, DB Agus, HP Koeffler; citation_volume=104; citation_publication_date=2005; citation_pages=2701-2708; citation_doi=10.1002/cncr.21533; citation_id=CR15 citation_journal_title=N Engl J Med; citation_title=The promise of antibody-drug conjugates; citation_author=BA Teicher, JH Doroshow; citation_volume=367; citation_publication_date=2012; citation_pages=1847-1848; citation_doi=10.1056/NEJMe1211736; citation_id=CR16 citation_journal_title=N Engl J Med; citation_title=Trastuzumab emtansine for HER2-positive advanced breast cancer; citation_author=S Verma, D Miles, L Gianni, IE Krop, M Welslau, J Baselga, M Pegram, DY Oh, V Dieras, E Guardino, L Fang, MW Lu, S Olsen, K Blackwell; citation_volume=367; citation_publication_date=2012; citation_pages=1783-1791; citation_doi=10.1056/NEJMoa1209124; citation_id=CR17 citation_journal_title=Cancer Treat Rev; citation_title=Activity and resistance of trastuzumab according to different clinical settings; citation_author=E Tagliabue, M Campiglio, SM Pupa, S Menard, A Balsari; citation_volume=38; citation_publication_date=2012; citation_pages=212-217; citation_doi=10.1016/j.ctrv.2011.06.002; citation_id=CR18 citation_journal_title=Clin Breast Cancer; citation_title=Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer; citation_author=M Piccart; citation_volume=8; citation_issue=Suppl 3; citation_publication_date=2008; citation_pages=S100-S113; citation_doi=10.3816/CBC.2008.s.006; citation_id=CR19 citation_journal_title=Haematologica; citation_title=CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q; citation_author=P Liebisch, S Eppinger, C Schopflin, G Stehle, G Munzert, H Dohner, M Schmid; citation_volume=90; citation_publication_date=2005; citation_pages=489-493; citation_id=CR20 citation_journal_title=N Engl J Med; citation_title=Bortezomib or high-dose dexamethasone for relapsed multiple myeloma; citation_author=PG Richardson, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, T Facon, JL Harousseau, D Ben-Yehuda, S Lonial, H Goldschmidt, D Reece, JF San-Miguel, J Blade, M Boccadoro, J Cavenagh, WS Dalton, AL Boral, DL Esseltine, JB Porter, D Schenkein, KC Anderson; citation_volume=352; citation_publication_date=2005; citation_pages=2487-2498; citation_doi=10.1056/NEJMoa043445; citation_id=CR21 citation_journal_title=J Clin Oncol; citation_title=Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor; citation_author=LB Saltz, NJ Meropol, PJ Loehrer, MN Needle, J Kopit, RJ Mayer; citation_volume=22; citation_publication_date=2004; citation_pages=1201-1208; citation_doi=10.1200/JCO.2004.10.182; citation_id=CR22 citation_journal_title=N Engl J Med; citation_title=Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer; citation_author=D Cunningham, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, D Bets, M Mueser, A Harstrick, C Verslype, I Chau, E Van Cutsem; citation_volume=351; citation_publication_date=2004; citation_pages=337-345; citation_doi=10.1056/NEJMoa033025; citation_id=CR23 citation_journal_title=J Clin Oncol; citation_title=Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines; citation_author=HJ Lenz, E Van Cutsem, S Khambata-Ford, RJ Mayer, P Gold, P Stella, B Mirtsching, AL Cohn, AW Pippas, N Azarnia, Z Tsuchihashi, DJ Mauro, EK Rowinsky; citation_volume=24; citation_publication_date=2006; citation_pages=4914-4921; citation_doi=10.1200/JCO.2006.06.7595; citation_id=CR24 citation_journal_title=J Clin Oncol; citation_title=Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer; citation_author=E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, JL Canon, JL Van Laethem, J Maurel, G Richardson, M Wolf, RG Amado; citation_volume=25; citation_publication_date=2007; citation_pages=1658-1664; citation_doi=10.1200/JCO.2006.08.1620; citation_id=CR25 citation_journal_title=J Clin Oncol; citation_title=American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy; citation_author=CJ Allegra, JM Jessup, MR Somerfield, SR Hamilton, EH Hammond, DF Hayes, PK McAllister, RF Morton, RL Schilsky; citation_volume=27; citation_publication_date=2009; citation_pages=2091-2096; citation_doi=10.1200/JCO.2009.21.9170; citation_id=CR26 citation_journal_title=J Oncol Pract; citation_title=ASCO provisional clinical opinion: KRAS, cetuximab, and panitumumab-clinical implications in colorectal cancer; citation_author=RF Morton, EH Hammond; citation_volume=5; citation_publication_date=2009; citation_pages=71-72; citation_doi=10.1200/JOP.0924603; citation_id=CR27 citation_journal_title=PLoS One; citation_title=Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer; citation_author=A Sartore-Bianchi, F Di Nicolantonio, M Nichelatti, F Molinari, S De Dosso, P Saletti, M Martini, T Cipani, G Marrapese, L Mazzucchelli, S Lamba, S Veronese, M Frattini, A Bardelli, S Siena; citation_volume=4; citation_publication_date=2009; citation_pages=e7287; citation_doi=10.1371/journal.pone.0007287; citation_id=CR28 citation_journal_title=Br J Cancer; citation_title=Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy; citation_author=F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, MP Galais, L Bastit, A Killian, R Sesboue, JJ Tuech, AM Queuniet, B Paillot, JC Sabourin, F Michot, P Michel, T Frebourg; citation_volume=96; citation_publication_date=2007; citation_pages=1166-1169; citation_doi=10.1038/sj.bjc.6603685; citation_id=CR29 citation_journal_title=Ann Oncol; citation_title=KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab; citation_author=W De Roock, H Piessevaux, J De Schutter, M Janssens, G De Hertogh, N Personeni, B Biesmans, JL Van Laethem, M Peeters, Y Humblet, E Van Cutsem, S Tejpar; citation_volume=19; citation_publication_date=2008; citation_pages=508-515; citation_doi=10.1093/annonc/mdm496; citation_id=CR30 citation_journal_title=N Engl J Med; citation_title=K-ras mutations and benefit from cetuximab in advanced colorectal cancer; citation_author=CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O’Callaghan, D Tu, NC Tebbutt, RJ Simes, H Chalchal, JD Shapiro, S Robitaille, TJ Price, L Shepherd, HJ Au, C Langer, MJ Moore, JR Zalcberg; citation_volume=359; citation_publication_date=2008; citation_pages=1757-1765; citation_doi=10.1056/NEJMoa0804385; citation_id=CR31 citation_journal_title=J Clin Oncol; citation_title=KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab; citation_author=A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, O Bouche, B Landi, C Louvet, T Andre, F Bibeau, MD Diebold, P Rougier, M Ducreux, G Tomasic, JF Emile, F Penault-Llorca, P Laurent-Puig; citation_volume=26; citation_publication_date=2008; citation_pages=374-379; citation_doi=10.1200/JCO.2007.12.5906; citation_id=CR32 citation_journal_title=Clin Colorectal Cancer; citation_title=Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone; citation_author=DJ Freeman, T Juan, M Reiner, JR Hecht, NJ Meropol, J Berlin, E Mitchell, I Sarosi, R Radinsky, RG Amado; citation_volume=7; citation_publication_date=2008; citation_pages=184-190; citation_doi=10.3816/CCC.2008.n.024; citation_id=CR33 citation_journal_title=J Clin Oncol; citation_title=Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer; citation_author=RG Amado, M Wolf, M Peeters, E Van Cutsem, S Siena, DJ Freeman, T Juan, R Sikorski, S Suggs, R Radinsky, SD Patterson, DD Chang; citation_volume=26; citation_publication_date=2008; citation_pages=1626-1634; citation_doi=10.1200/JCO.2007.14.7116; citation_id=CR34 citation_journal_title=Int J Cancer; citation_title=Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer; citation_author=G Perkins, A Lievre, C Ramacci, T Meatchi, A de Reynies, JF Emile, V Boige, G Tomasic, JB Bachet, F Bibeau, O Bouche, F Penault-Llorca, JL Merlin, P Laurent-Puig; citation_volume=127; citation_publication_date=2010; citation_pages=1321-1331; citation_doi=10.1002/ijc.25152; citation_id=CR35 citation_journal_title=Cancer Res; citation_title=KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer; citation_author=A Lievre, JB Bachet, D Le Corre, V Boige, B Landi, JF Emile, JF Cote, G Tomasic, C Penna, M Ducreux, P Rougier, F Penault-Llorca, P Laurent-Puig; citation_volume=66; citation_publication_date=2006; citation_pages=3992-3995; citation_doi=10.1158/0008-5472.CAN-06-0191; citation_id=CR36 citation_journal_title=PLoS One; citation_title=Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients; citation_author=Z Saridaki, M Tzardi, C Papadaki, M Sfakianaki, F Pega, A Kalikaki, E Tsakalaki, M Trypaki, I Messaritakis, E Stathopoulos, D Mavroudis, V Georgoulias, J Souglakos; citation_volume=6; citation_publication_date=2011; citation_pages=e15980; citation_doi=10.1371/journal.pone.0015980; citation_id=CR37 citation_journal_title=N Engl J Med; citation_title=Lapatinib plus capecitabine for HER2-positive advanced breast cancer; citation_author=CE Geyer, J Forster, D Lindquist, S Chan, CG Romieu, T Pienkowski, A Jagiello-Gruszfeld, J Crown, A Chan, B Kaufman, D Skarlos, M Campone, N Davidson, M Berger, C Oliva, SD Rubin, S Stein, D Cameron; citation_volume=355; citation_publication_date=2006; citation_pages=2733-2743; citation_doi=10.1056/NEJMoa064320; citation_id=CR38 citation_journal_title=J Clin Oncol; citation_title=Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study; citation_author=G von Minckwitz, A du Bois, M Schmidt, N Maass, T Cufer, FE de Jongh, E Maartense, C Zielinski, M Kaufmann, W Bauer, KH Baumann, MR Clemens, R Duerr, C Uleer, M Andersson, RC Stein, V Nekljudova, S Loibl; citation_volume=27; citation_publication_date=2009; citation_pages=1999-2006; citation_doi=10.1200/JCO.2008.19.6618; citation_id=CR39 citation_journal_title=N Engl J Med; citation_title=Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer; citation_author=H Hurwitz, L Fehrenbacher, W Novotny, T Cartwright, J Hainsworth, W Heim, J Berlin, A Baron, S Griffing, E Holmgren, N Ferrara, G Fyfe, B Rogers, R Ross, F Kabbinavar; citation_volume=350; citation_publication_date=2004; citation_pages=2335-2342; citation_doi=10.1056/NEJMoa032691; citation_id=CR40 citation_journal_title=N Engl J Med; citation_title=Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer; citation_author=A Sandler, R Gray, MC Perry, J Brahmer, JH Schiller, A Dowlati, R Lilenbaum, DH Johnson; citation_volume=355; citation_publication_date=2006; citation_pages=2542-2550; citation_doi=10.1056/NEJMoa061884; citation_id=CR41 citation_journal_title=Breast Cancer Res Treat; citation_title=Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials; citation_author=A Valachis, NP Polyzos, NA Patsopoulos, V Georgoulias, D Mavroudis, D Mauri; citation_volume=122; citation_publication_date=2010; citation_pages=1-7; citation_doi=10.1007/s10549-009-0727-0; citation_id=CR42 citation_journal_title=Biochem Biophys Res Commun; citation_title=IGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model; citation_author=Y Jia, Y Zhang, C Qiao, G Liu, Q Zhao, T Zhou, G Chen, Y Li, J Feng, Q Zhang, H Peng; citation_volume=436; citation_publication_date=2013; citation_pages=740-745; citation_doi=10.1016/j.bbrc.2013.06.030; citation_id=CR43 citation_journal_title=Plasmid; citation_title=Development of a doxycycline-inducible lentiviral plasmid with an instant regulatory feature; citation_author=T Yang, C Burrows, JH Park; citation_volume=72; citation_publication_date=2014; citation_pages=29-35; citation_doi=10.1016/j.plasmid.2014.04.001; citation_id=CR44 citation_journal_title=Nat Rev Cancer; citation_title=Insulin and insulin-like growth factor signalling in neoplasia; citation_author=M Pollak; citation_volume=8; citation_publication_date=2008; citation_pages=915-928; citation_doi=10.1038/nrc2536; citation_id=CR45 citation_journal_title=Exp Cell Res; citation_title=The IGF-I receptor in cancer research; citation_author=R Baserga; citation_volume=253; citation_publication_date=1999; citation_pages=1-6; citation_doi=10.1006/excr.1999.4667; citation_id=CR46 citation_journal_title=Nat Rev Cancer; citation_title=Insulin-like growth factors and neoplasia; citation_author=MN Pollak, ES Schernhammer, SE Hankinson; citation_volume=4; citation_publication_date=2004; citation_pages=505-518; citation_doi=10.1038/nrc1387; citation_id=CR47 citation_journal_title=Curr Opin Pharmacol; citation_title=Involvement of insulin-like growth factor-I in the control of glucose homeostasis; citation_author=DR Clemmons; citation_volume=6; citation_publication_date=2006; citation_pages=620-625; citation_doi=10.1016/j.coph.2006.08.006; citation_id=CR48 citation_journal_title=Nat Clin Pract Endocrinol Metab; citation_title=Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1; citation_author=D LeRoith, S Yakar; citation_volume=3; citation_publication_date=2007; citation_pages=302-310; citation_doi=10.1038/ncpendmet0427; citation_id=CR49 citation_journal_title=Cancer Res; citation_title=Insulin-like growth factor receptor expression and function in human breast cancer; citation_author=KJ Cullen, D Yee, WS Sly, J Perdue, B Hampton, ME Lippman, N Rosen; citation_volume=50; citation_publication_date=1990; citation_pages=48-53; citation_id=CR50 citation_journal_title=Breast Cancer Res Treat; citation_title=Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death–proliferative and anti-apoptotic effects; citation_author=JL Gooch, CL Van Den Berg, D Yee; citation_volume=56; citation_publication_date=1999; citation_pages=1-10; citation_doi=10.1023/A:1006208721167; citation_id=CR51 citation_journal_title=Biomed Pharmacother; citation_title=Insulin-like growth factors and breast cancer; citation_author=AV Lee, D Yee; citation_volume=49; citation_publication_date=1995; citation_pages=415-421; citation_doi=10.1016/0753-3322(96)82678-3; citation_id=CR52 citation_journal_title=Breast Cancer Res Treat; citation_title=Type 1 IGF receptor in human breast diseases; citation_author=JP Peyrat, J Bonneterre; citation_volume=22; citation_publication_date=1992; citation_pages=59-67; citation_doi=10.1007/BF01833334; citation_id=CR53 citation_journal_title=Ann Oncol; citation_title=The insulin-like growth factor system as a therapeutic target in colorectal cancer; citation_author=AB Hassan, VM Macaulay; citation_volume=13; citation_publication_date=2002; citation_pages=349-356; citation_doi=10.1093/annonc/mdf096; citation_id=CR54 citation_journal_title=Cancer Res; citation_title=Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis; citation_author=Y Wu, S Yakar, L Zhao, L Hennighausen, D LeRoith; citation_volume=62; citation_publication_date=2002; citation_pages=1030-1035; citation_id=CR55 citation_journal_title=Cancer Res; citation_title=In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR); citation_author=T Nickerson, F Chang, D Lorimer, SP Smeekens, CL Sawyers, M Pollak; citation_volume=61; citation_publication_date=2001; citation_pages=6276-6280; citation_id=CR56 citation_journal_title=Blood; citation_title=Insulin-like growth factor I is a dual effector of multiple myeloma cell growth; citation_author=NL Ge, S Rudikoff; citation_volume=96; citation_publication_date=2000; citation_pages=2856-2861; citation_id=CR57 citation_journal_title=Endocr Relat Cancer; citation_title=Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer; citation_author=JM Gee, JF Robertson, E Gutteridge, IO Ellis, SE Pinder, M Rubini, RI Nicholson; citation_volume=12; citation_issue=Suppl 1; citation_publication_date=2005; citation_pages=S99-S111; citation_doi=10.1677/erc.1.01005; citation_id=CR58 citation_journal_title=Cancer Cell; citation_title=Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K; citation_author=J Villanueva, A Vultur, JT Lee, R Somasundaram, M Fukunaga-Kalabis, AK Cipolla, B Wubbenhorst, X Xu, PA Gimotty, D Kee, AE Santiago-Walker, R Letrero, K D’Andrea, A Pushparajan, JE Hayden, KD Brown, S Laquerre, GA McArthur, JA Sosman, KL Nathanson, M Herlyn; citation_volume=18; citation_publication_date=2010; citation_pages=683-695; citation_doi=10.1016/j.ccr.2010.11.023; citation_id=CR59 citation_journal_title=Mol Cancer Ther; citation_title=Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody; citation_author=DH Shin, HY Min, AK El-Naggar, SM Lippman, B Glisson, HY Lee; citation_volume=10; citation_publication_date=2011; citation_pages=2437-2448; citation_doi=10.1158/1535-7163.MCT-11-0235; citation_id=CR60 citation_journal_title=Hum Pathol; citation_title=Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett’s neoplasia; citation_author=S Iravani, HQ Zhang, ZQ Yuan, JQ Cheng, RC Karl, R Jove, D Coppola; citation_volume=34; citation_publication_date=2003; citation_pages=975-982; citation_doi=10.1053/S0046-8177(03)00354-X; citation_id=CR61 citation_journal_title=Ann Intern Med; citation_title=Insulin-like growth factors and cancer; citation_author=D LeRoith, R Baserga, L Helman, CT Roberts; citation_volume=122; citation_publication_date=1995; citation_pages=54-59; citation_doi=10.7326/0003-4819-122-1-199501010-00009; citation_id=CR62 citation_journal_title=Cancer Res; citation_title=Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors; citation_author=EM Berns, JG Klijn, IL van Staveren, H Portengen, JA Foekens; citation_volume=52; citation_publication_date=1992; citation_pages=1036-1039; citation_id=CR63 citation_journal_title=Oncogene; citation_title=Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors; citation_author=AT De Souza, GR Hankins, MK Washington, RL Fine, TC Orton, RL Jirtle; citation_volume=10; citation_publication_date=1995; citation_pages=1725-1729; citation_id=CR64 citation_journal_title=Science; citation_title=Loss of IGF2 imprinting: a potential marker of colorectal cancer risk; citation_author=H Cui, M Cruz-Correa, FM Giardiello, DF Hutcheon, DR Kafonek, S Brandenburg, Y Wu, X He, NR Powe, AP Feinberg; citation_volume=299; citation_publication_date=2003; citation_pages=1753-1755; citation_doi=10.1126/science.1080902; citation_id=CR65 citation_journal_title=Cancer Res; citation_title=Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk; citation_author=A Kaneda, AP Feinberg; citation_volume=65; citation_publication_date=2005; citation_pages=11236-11240; citation_doi=10.1158/0008-5472.CAN-05-2959; citation_id=CR66 citation_journal_title=J Hepatol; citation_title=A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma; citation_author=GK Abou-Alfa, M Capanu, EM O’Reilly, J Ma, JF Chou, B Gansukh, J Shia, M Kalin, S Katz, L Abad, DL Reidy-Lagunes, DP Kelsen, HX Chen, LB Saltz; citation_volume=60; citation_publication_date=2014; citation_pages=319-324; citation_doi=10.1016/j.jhep.2013.09.008; citation_id=CR67 citation_journal_title=Eur J Cancer; citation_title=Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells; citation_author=Z Attias-Geva, I Bentov, DL Ludwig, A Fishman, I Bruchim, H Werner; citation_volume=47; citation_publication_date=2011; citation_pages=1717-1726; citation_doi=10.1016/j.ejca.2011.02.019; citation_id=CR68 citation_journal_title=Clin Cancer Res; citation_title=IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor; citation_author=EK Rowinsky, H Youssoufian, JR Tonra, P Solomon, D Burtrum, DL Ludwig; citation_volume=13; citation_publication_date=2007; citation_pages=5549s-5555s; citation_doi=10.1158/1078-0432.CCR-07-1109; citation_id=CR69 citation_journal_title=Clin Cancer Res; citation_title=A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer; citation_author=KN Chi, ME Gleave, L Fazli, SL Goldenberg, A So, C Kollmannsberger, N Murray, A Tinker, M Pollak; citation_volume=18; citation_publication_date=2012; citation_pages=3407-3413; citation_doi=10.1158/1078-0432.CCR-12-0482; citation_id=CR70 citation_journal_title=Clin Cancer Res; citation_title=Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer; citation_author=JS de Bono, JM Piulats, HS Pandha, DP Petrylak, F Saad, LM Aparicio, SK Sandhu, P Fong, S Gillessen, GR Hudes, T Wang, J Scranton, MN Pollak; citation_volume=20; citation_publication_date=2014; citation_pages=1925-1934; citation_doi=10.1158/1078-0432.CCR-13-1869; citation_id=CR71 citation_journal_title=Clin Lung Cancer; citation_title=Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer; citation_author=A Gualberto, DD Karp; citation_volume=10; citation_publication_date=2009; citation_pages=273-280; citation_doi=10.3816/CLC.2009.n.038; citation_id=CR72 citation_journal_title=J Clin Oncol; citation_title=Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer; citation_author=CJ Langer, S Novello, K Park, M Krzakowski, DD Karp, T Mok, RJ Benner, JR Scranton, AJ Olszanski, J Jassem; citation_volume=32; citation_publication_date=2014; citation_pages=2059-2066; citation_doi=10.1200/JCO.2013.54.4932; citation_id=CR73 citation_journal_title=Ann Oncol; citation_title=Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008–02); citation_author=S Schmitz, MC Kaminsky-Forrett, S Henry, S Zanetta, L Geoffrois, E Bompas, A Moxhon, L Mignion, J Guigay, L Knoops, M Hamoir, JP Machiels; citation_volume=23; citation_publication_date=2012; citation_pages=2153-2161; citation_doi=10.1093/annonc/mdr574; citation_id=CR74 citation_journal_title=Clin Cancer Res; citation_title=A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors; citation_author=F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, E Rodriguez-Braun, A Domingo, J Guijarro, C Gamez, J Rodon, S Di Cosimo, H Brown, J Clark, JS Hardwick, RA Beckman, WD Hanley, K Hsu, E Calvo, S Rosello, RB Langdon, J Baselga; citation_volume=17; citation_publication_date=2011; citation_pages=6304-6312; citation_doi=10.1158/1078-0432.CCR-10-3336; citation_id=CR75 citation_journal_title=J Thorac Oncol; citation_title=NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer; citation_author=PM Ellis, FA Shepherd, SA Laurie, GD Goss, M Olivo, J Powers, L Seymour, PA Bradbury; citation_volume=9; citation_publication_date=2014; citation_pages=410-413; citation_doi=10.1097/JTO.0000000000000058; citation_id=CR76 citation_journal_title=Curr Opin Mol Ther; citation_title=Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer; citation_author=M Scartozzi, M Bianconi, E Maccaroni, R Giampieri, R Berardi, S Cascinu; citation_volume=12; citation_publication_date=2010; citation_pages=361-371; citation_id=CR77 citation_journal_title=Clin Cancer Res; citation_title=Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy; citation_author=PJ Beltran, FJ Calzone, P Mitchell, YA Chung, E Cajulis, G Moody, B Belmontes, CM Li, S Vonderfecht, VE Velculescu, G Yang, J Qi, DJ Slamon, GE Konecny; citation_volume=20; citation_publication_date=2014; citation_pages=2947-2958; citation_doi=10.1158/1078-0432.CCR-13-3448; citation_id=CR78 citation_journal_title=Endocr Relat Cancer; citation_title=A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors; citation_author=JR Strosberg, JA Chan, DP Ryan, JA Meyerhardt, CS Fuchs, T Abrams, E Regan, R Brady, J Weber, T Campos, LK Kvols, MH Kulke; citation_volume=20; citation_publication_date=2013; citation_pages=383-390; citation_doi=10.1530/ERC-12-0390; citation_id=CR79 citation_journal_title=J Clin Oncol; citation_title=Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors; citation_author=WD Tap, G Demetri, P Barnette, J Desai, P Kavan, R Tozer, PW Benedetto, G Friberg, H Deng, I McCaffery, I Leitch, S Badola, S Chang, M Zhu, A Tolcher; citation_volume=30; citation_publication_date=2012; citation_pages=1849-1856; citation_doi=10.1200/JCO.2011.37.2359; citation_id=CR80 citation_journal_title=Clin Cancer Res; citation_title=Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer; citation_author=E Van Cutsem, C Eng, E Nowara, A Swieboda-Sadlej, N Tebbutt, EP Mitchell, I Davidenko, J Stephenson, ME Elez, H Prenen, H Deng, R Tang, I McCaffery, K Oliner, L Chen, JL Gansert, E Loh, D Smethurst, J Tabernero; citation_volume=20; citation_publication_date=2014; citation_pages=4240-4250; citation_doi=10.1158/1078-0432.CCR-13-2752; citation_id=CR81 citation_journal_title=J Clin Oncol; citation_title=R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study; citation_author=AS Pappo, SR Patel, J Crowley, DK Reinke, KP Kuenkele, SP Chawla, GC Toner, RG Maki, PA Meyers, R Chugh, KN Ganjoo, SM Schuetze, H Juergens, MG Leahy, B Geoerger, RS Benjamin, LJ Helman, LH Baker; citation_volume=29; citation_publication_date=2011; citation_pages=4541-4547; citation_doi=10.1200/JCO.2010.34.0000; citation_id=CR82 citation_journal_title=Cancer Med; citation_title=A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer; citation_author=EH Lin, HJ Lenz, MN Saleh, MJ Mackenzie, JA Knost, K Pathiraja, RB Langdon, SL Yao, BD Lu; citation_volume=29; citation_publication_date=2014; citation_pages=4541-4547; citation_id=CR83 citation_journal_title=Ann Oncol; citation_title=Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors; citation_author=VM Macaulay, MR Middleton, AS Protheroe, A Tolcher, V Dieras, C Sessa, R Bahleda, JY Blay, P LoRusso, D Mery-Mignard, JC Soria; citation_volume=24; citation_publication_date=2013; citation_pages=784-791; citation_doi=10.1093/annonc/mds511; citation_id=CR84 citation_journal_title=Leukemia; citation_title=Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma; citation_author=P Moreau, F Cavallo, X Leleu, C Hulin, M Amiot, G Descamps, T Facon, M Boccadoro, D Mignard, JL Harousseau; citation_volume=25; citation_publication_date=2011; citation_pages=872-874; citation_doi=10.1038/leu.2011.4; citation_id=CR85 citation_journal_title=Invest New Drugs; citation_title=A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors; citation_author=M von Mehren, CD Britten, P Pieslor, W Saville, A Vassos, S Harris, GR Galluppi, M Darif, ZA Wainberg, RB Cohen, S Leong; citation_volume=32; citation_publication_date=2014; citation_pages=518-525; citation_doi=10.1007/s10637-014-0064-y; citation_id=CR86 citation_journal_title=Cancer Res; citation_title=A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo; citation_author=D Burtrum, Z Zhu, D Lu, DM Anderson, M Prewett, DS Pereira, R Bassi, R Abdullah, AT Hooper, H Koo, X Jimenez, D Johnson, R Apblett, P Kussie, P Bohlen, L Witte, DJ Hicklin, DL Ludwig; citation_volume=63; citation_publication_date=2003; citation_pages=8912-8921; citation_id=CR87 citation_journal_title=Clin Cancer Res; citation_title=Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871; citation_author=BD Cohen, DA Baker, C Soderstrom, G Tkalcevic, AM Rossi, PE Miller, MW Tengowski, F Wang, A Gualberto, JS Beebe, JD Moyer; citation_volume=11; citation_publication_date=2005; citation_pages=2063-2073; citation_doi=10.1158/1078-0432.CCR-04-1070; citation_id=CR88 citation_journal_title=Cancer Res; citation_title=Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells; citation_author=R Nahta, LX Yuan, B Zhang, R Kobayashi, FJ Esteva; citation_volume=65; citation_publication_date=2005; citation_pages=11118-11128; citation_doi=10.1158/0008-5472.CAN-04-3841; citation_id=CR89